Difference between revisions of "Filgrastim (Neupogen)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| Line 10: | Line 10: | ||
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
| + | *[[B-cell acute lymphoblastic leukemia]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 26: | Line 27: | ||
==Also known as== | ==Also known as== | ||
| − | {| | + | *'''Generic names:''' filgrastim, GCSF, G-CSF, granulocyte colony stimulating factor |
| + | *'''Brand names:''' | ||
| + | {| class="wikitable" style="text-align:center;" | ||
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms''' | !colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms''' | ||
|- | |- | ||
| − | |||
|Biocilin | |Biocilin | ||
|Biofigran | |Biofigran | ||
| Line 36: | Line 38: | ||
|Filatil | |Filatil | ||
|Filgen | |Filgen | ||
| − | |||
| − | |||
|Filgrastima | |Filgrastima | ||
| − | |||
| − | |||
|Gran | |Gran | ||
| − | | | + | |- |
| − | |||
| − | |||
|Granulokine | |Granulokine | ||
| − | |||
|Grasalva | |Grasalva | ||
|Grasin | |Grasin | ||
| Line 54: | Line 49: | ||
|Leucin | |Leucin | ||
|Leucocim | |Leucocim | ||
| + | |- | ||
|Leucokain | |Leucokain | ||
| − | |||
|Leucostim | |Leucostim | ||
|Leukokine | |Leukokine | ||
|Leumostin | |Leumostin | ||
|Lioplim | |Lioplim | ||
| − | |||
|Mielastra | |Mielastra | ||
|Myelostim | |Myelostim | ||
| Line 68: | Line 62: | ||
|Neukine | |Neukine | ||
|Neupogen | |Neupogen | ||
| − | |||
| − | |||
| − | |||
|Nevkine | |Nevkine | ||
|Nivestim | |Nivestim | ||
| + | |Topneuter | ||
| + | | | ||
| + | | | ||
|- | |- | ||
| − | |||
| − | |||
| − | |||
| − | |||
|} | |} | ||
| Line 89: | Line 79: | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
| + | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
[[Category:FDA approved in 1991]] | [[Category:FDA approved in 1991]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 18:14, 22 August 2018
General information
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation‚ differentiation, and some end-cell functional activation.[1][2][3]
Route: SC, IV
Extravasation: no known issues
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Note that colony stimulating factors are used for their adjuvant effect e.g. removing leukemia stem cells from their protective niches; they are not thought to have inherent anti-cancer activity.
Patient drug information
- Filgrastim (Neupogen) package insert[1]
- Filgrastim (Neupogen) patient drug information (Chemocare)[4]
- Filgrastim (Neupogen) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2/20/1991: Initial FDA approval.
- Currently approved to:
- "Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever"
- "Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)"
- "Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)"
- "Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis"
- "Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia"
Also known as
- Generic names: filgrastim, GCSF, G-CSF, granulocyte colony stimulating factor
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Biocilin | Biofigran | Biofilgran | Euprotin | Filatil | Filgen | Filgrastima | Gran |
| Granulokine | Grasalva | Grasin | Grastim | Leicita | Leubene | Leucin | Leucocim |
| Leucokain | Leucostim | Leukokine | Leumostin | Lioplim | Mielastra | Myelostim | Neipogen |
| Neitrostim | Neukine | Neupogen | Nevkine | Nivestim | Topneuter | ||